News FDA fast tracks Shire clotting disease drug The US regulator has given a Fast Track designation to a Shire pipeline drug for a life-threatening blood clotting disease, hereditary thrombotic thrombocytopenic purpura.
News Drug price controversies hit pharma's reputation Patient groups slam pharma over drug costs in latest survey.
Views & Analysis Orphan drugs will fuel pharma's future - and a pricing pushb... Evaluate predicts sales could approach $8bn if approved.
News Patient death raises concerns over Roche haemophilia drug Concerns following event on HAVEN1 trial.
News Shire looks to eye drug as sales beat forecasts Company reports better than expected full year figures.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.